The news couldn't have been better for Vanda Pharmaceuticals (VNDA), with an FDA panel voting positively by overwhelming margins on all 5 questions relating to tasimelteon.
The panel voted 10-1 that substantial evidence of efficacy has been presented for the drug in non-24 and 11-0 that safety issues have been adequately addressed.
Frequent biotech company bear Adam Feuerstein: "It was tasimelteon love-fest at the FDA panel. Never seen a company so dominate proceedings."
VNDA shares remain halted.
Previous: FDA votes 10-1 in favor of Vanda clinical endpoints
Subscribe for full text news in your inbox